SLC2A3 and lymphoma: In acute myeloid leukemia (AML), a SLC2A3-knockdown cell line accounted for the less effective demethylation and vitamin C in the AML and lymphoma cell lines suggesting SLC2A3 could act as a predictive biomarker in vitamin C treatment in AML [24].